Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia
Por:
Ribera, JM, Morgades, M, Montesinos, P, Martino, R, Barba, P, Soria, B, Bermudez, A, Moreno, MJ, Gonzalez-Campos, J, Vives, S, Gil, C, Abella, E, Guardia, R, Martinez-Carballeira, D, Martinez-Sanchez, P, Amigo, ML, Mercadal, S, Serrano, A, Lopez-Martinez, A, Vall-Llovera, F, Sanchez-Sanchez, MJ, Penarrubia, MJ, Calbacho, M, Mendez, JA, Bergua, J, Cladera, A, Tormo, M, Garcia-Belmonte, D, Feliu, E, Ciudad, J, Orfao, A
Publicada:
1 ene 2018
Resumen:
Native or pegylated (PEG) asparaginase (ASP) are commonly used in treatment of acute lymphoblastic leukemia (ALL), but have been scarcely compared in the same trial in adult patients. Native vs. PEG-ASP administered according to availability in each center were prospectively evaluated in adults with high-risk ALL. Ninety-one patients received native ASP and 35 PEG-ASP in induction. No significant differences were observed in complete remission, minimal residual disease levels after induction and after consolidation, disease-free survival, and overall survival. No significant differences in grades 3-4 toxicity were observed in the induction period, although a trend for higher hepatic toxicity was observed in patients receiving PEG-ASP. In this trial the type of ASP did not influence patient response and outcome.
Filiaciones:
Ribera, JM:
ICO Badalona Hosp Germans Trias Pujol, Univ Autnoma Barcelona, Josep Carreras Leukemia Res Inst, Badalona, Spain
Morgades, M:
ICO Badalona Hosp Germans Trias Pujol, Univ Autnoma Barcelona, Josep Carreras Leukemia Res Inst, Badalona, Spain
Montesinos, P:
Hosp Univ Politecn Fe, Valencia, Spain
Martino, R:
Hosp Santa Creu & Sant Pau, Barcelona, Spain
Barba, P:
Hosp Vall dHebron Univ Autnoma Barcelona, Barcelona, Spain
Soria, B:
Hosp Univ Canarias, Santa Cruz De Tenerife, Spain
Bermudez, A:
Hosp Univ Marques Valdecilla, Santander, Spain
Moreno, MJ:
Hosp Clinico Univ Virgen Victoria, Malaga, Spain
Gonzalez-Campos, J:
Hosp Univ Virgen Rocio, Seville, Spain
Vives, S:
ICO Badalona Hosp Germans Trias Pujol, Univ Autnoma Barcelona, Josep Carreras Leukemia Res Inst, Badalona, Spain
Gil, C:
Hosp Gen Alicante, Alicante, Spain
Abella, E:
Hosp Mar, Barcelona, Spain
Guardia, R:
ICO Girona Hosp Josep Trueta, Girona, Spain
Martinez-Carballeira, D:
Hosp Univ Cent Asturias, Oviedo, Spain
Martinez-Sanchez, P:
Hosp Univ Doce Octubre, Madrid, Spain
Amigo, ML:
Hosp Morales Meseguer, Murcia, Spain
Mercadal, S:
ICO LHospitalet Hosp Duran Reynals, Lhospitalet De Llobregat, Spain
Serrano, A:
Hosp Madrid Sanchinarro, Madrid, Spain
Lopez-Martinez, A:
Hosp Arnau Vilanova, Valencia, Spain
Vall-Llovera, F:
Hosp Univ Mutua Terrassa, Terrassa, Spain
Sanchez-Sanchez, MJ:
Hosp Lucus Augusti, Lugo, Spain
Penarrubia, MJ:
Hosp Clinico Univ Valladolid, Valladolid, Spain
Calbacho, M:
Hosp Ramon & Cajal, Madrid, Spain
Mendez, JA:
Complejo Hospitalario Univ Ourense, Orense, Spain
Bergua, J:
Hosp San Pedro Alcantara, Caceres, Spain
Cladera, A:
Hosp Son Llatzer, Palma De Mallorca, Spain
Tormo, M:
Hosp Clinico Univ Valencia, Valencia, Spain
Garcia-Belmonte, D:
Hosp Zarzuela, Madrid, Spain
Feliu, E:
ICO Badalona Hosp Germans Trias Pujol, Univ Autnoma Barcelona, Josep Carreras Leukemia Res Inst, Badalona, Spain
Ciudad, J:
Univ Salamanca, & Inst Investigac Biomed Salamanca IBSAL, Centro Investigac Canc CIC, IBMCC USAL CSIC, Salamanca, Spain
Orfao, A:
Univ Salamanca, & Inst Investigac Biomed Salamanca IBSAL, Centro Investigac Canc CIC, IBMCC USAL CSIC, Salamanca, Spain
|